Myeloproliferative Disorder Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (Polycythaemia Vera, Essential Thrombocythemia, Myelofibrosis, Other), By Treatment, By End-Use, By Region, And Segment Forecasts, 2023 - 2032
The global myeloproliferative disorders treatment market size is expected to reach USD 13.13 billion by 2032, according to a new study by Polaris Market Research. The report “Myeloproliferative Disorder Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (Polycythaemia Vera, Essential Thrombocythemia, Myelofibrosis, Other), By Treatment, By End-Use, By Region, And Segment Forecasts, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.
There is a growing availability of novel drugs and a strong pipeline of potential treatments. This has created optimism for more effective therapies in the future, driving interest and investment in the market. The rising incidence of myeloproliferative disorders can be attributed to changing lifestyles and an aging population. These factors have contributed to an increase in the number of individuals at risk of developing these conditions, leading to a higher demand for treatments.
Additionally, there is a heightened level of public awareness regarding myeloproliferative disorders. This increased awareness has led to earlier diagnosis and treatment, further fueling the demand for therapies in the market. Furthermore, the development of therapeutic options for patients who are intolerant to Jakafi, a commonly used medication for myeloproliferative disorders, is a notable trend. This second-line treatment approach addresses the needs of patients who may not respond well to Jakafi, expanding the market's potential patient base.
Chronic myeloproliferative disorders (MPDs) are a group of rare hematological malignancies characterized by the abnormal proliferation of certain types of blood cells in the bone marrow and peripheral blood. These disorders primarily affect the myeloid cell line, which includes red blood cells, granulocytes (a type of white blood cell), and platelets, as well as their precursor cells. These disorders are further categorized based on the presence or absence of the Philadelphia chromosome. The Philadelphia chromosome is a specific genetic abnormality resulting from a translocation (exchange of genetic material) between chromosomes 9 and 22. Its presence is a defining characteristic of CML.
Chronic myeloproliferative disorders are complex conditions that require careful diagnosis and management by healthcare professionals. Treatment options may include medications to control blood cell counts, manage symptoms, and reduce the risk of complications. In some cases, stem cell transplantation may be considered as a curative treatment option.
The higher incidence of myeloproliferative disorders (MPNs) in North America & Western Europe compared to East-Asian countries can be attributed to various factors, including differences in genetic predisposition, lifestyle, and environmental factors. While most MPN patients are diagnosed after the age of 60, these disorders can affect individuals of any age. The United States is poised to be the most prominent market for MPN drugs due to its substantial target population, advanced healthcare infrastructure, and significant investments in research and development, leading to the availability of innovative treatments for MPNs.
Myeloproliferative Disorders Treatment Market Report Highlights
The myelofibrosis segment held the largest share, owing to rising cases & increased research & development efforts to increase the efficacy of the treatment procedures
Chemotherapy segment led the market on account of a surge in cases of cancers due to changes in diet and busier lifestyle
North America garnered the largest share due to the presence of well-developed medical infrastructure, & huge industry-academia efforts for research & innovations
Key players include Novartis, Bristol-Myers, Incyte Corp, Takeda Pharmaceutical, Viatris, AbbVie, and Teva Pharmaceuticals
Polaris Market Research has segmented the myeloproliferative disorders treatment market report based on type, treatment, end-use, and region:
Myeloproliferative Disorders Treatment, Type Outlook (Revenue - USD Billion, 2023 - 2032)
Polycythaemia Vera
Essential Thrombocythemia
Myelofibrosis
Others
Myeloproliferative Disorders Treatment, Treatment Outlook (Revenue - USD Billion, 2023 - 2032)
Chemotherapy
Immunotherapy
Stem Cell Transplantation
Others
Myeloproliferative Disorders Treatment, End-Use Outlook (Revenue - USD Billion, 2023 - 2032)
Hospitals
Specialty Clinics
Others
Myeloproliferative Disorders Treatment, Regional Outlook (Revenue - USD Billion, 2023 - 2032)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. Global Myeloproliferative Disorder Treatment Market Insights
- 4.1. Myeloproliferative Disorder Treatment Market – End-Use Snapshot
- 4.2. Myeloproliferative Disorder Treatment Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Growing demand for effective treatments
- 4.2.1.2. Advancements in R&D and molecular understanding
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Limited treatment options
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Myeloproliferative Disorder Treatment Market End-Use Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
- 5. Global Myeloproliferative Disorder Treatment Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 5.3. Polycythaemia Vera
- 5.3.1. Global Myeloproliferative Disorder Treatment Market, by Polycythaemia Vera, by Region, 2019-2032 (USD Billion)
- 5.4. Essential Thrombocythemia
- 5.4.1. Global Myeloproliferative Disorder Treatment Market, by Essential Thrombocythemia, by Region, 2019-2032 (USD Billion)
- 5.5. Myelofibrosis
- 5.5.1. Global Myeloproliferative Disorder Treatment Market, by Myelofibrosis, by Region, 2019-2032 (USD Billion)
- 5.6. Other
- 5.6.1. Global Myeloproliferative Disorder Treatment Market, by Other, by Region, 2019-2032 (USD Billion)
- 6. Global Myeloproliferative Disorder Treatment Market, by Treatment
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 6.3. Chemotherapy
- 6.3.1. Global Myeloproliferative Disorder Treatment Market, by Chemotherapy, by Region, 2019-2032 (USD Billion)
- 6.4. Immunotherapy
- 6.4.1. Global Myeloproliferative Disorder Treatment Market, by Immunotherapy, by Region, 2019-2032 (USD Billion)
- 6.5. Stem Cell Transplantation
- 6.5.1. Global Myeloproliferative Disorder Treatment Market, by Stem Cell Transplantation, by Region, 2019-2032 (USD Billion)
- 6.6. Other
- 6.6.1. Global Myeloproliferative Disorder Treatment Market, by Other, by Region, 2019-2032 (USD Billion)
- 7. Global Myeloproliferative Disorder Treatment Market, by End-Use
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 7.3. Hospitals
- 7.3.1. Global Myeloproliferative Disorder Treatment Market, by Hospitals, By Region, 2019-2032 (USD Billion)
- 7.4. Specialty Clinics
- 7.4.1. Global Myeloproliferative Disorder Treatment Market, by Specialty Clinics, By Region, 2019-2032 (USD Billion)
- 7.5. Other
- 7.5.1. Global Myeloproliferative Disorder Treatment Market, by Other, By Region, 2019-2032 (USD Billion)
- 8. Global Myeloproliferative Disorder Treatment Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Myeloproliferative Disorder Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
- 8.3. Myeloproliferative Disorder Treatment Market – North America
- 8.3.1. North America: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.3.2. North America: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.3.3. North America: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.3.4. Myeloproliferative Disorder Treatment Market – U.S.
- 8.3.4.1. U.S.: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.3.4.2. U.S.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.3.4.3. U.S.: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.3.5. Myeloproliferative Disorder Treatment Market – Canada
- 8.3.5.1. Canada: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.3.5.2. Canada.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.3.5.3. Canada: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.4. Myeloproliferative Disorder Treatment Market – Europe
- 8.4.1. Europe: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.4.2. Europe.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.4.3. Europe: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.4.4. Myeloproliferative Disorder Treatment Market – UK
- 8.4.4.1. UK: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.4.4.2. UK.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.4.4.3. UK: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.4.5. Myeloproliferative Disorder Treatment Market – France
- 8.4.5.1. France: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.4.5.2. France.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.4.5.3. France: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.4.6. Myeloproliferative Disorder Treatment Market – Germany
- 8.4.6.1. Germany: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.4.6.2. Germany.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.4.6.3. Germany: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.4.7. Myeloproliferative Disorder Treatment Market – Italy
- 8.4.7.1. Italy: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.4.7.2. Italy.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.4.7.3. Italy: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.4.8. Myeloproliferative Disorder Treatment Market – Spain
- 8.4.8.1. Spain: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.4.8.2. Spain.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.4.8.3. Spain: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.4.9. Myeloproliferative Disorder Treatment Market – Netherlands
- 8.4.9.1. Netherlands: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.4.9.2. Netherlands.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.4.9.3. Netherlands: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.4.10. Myeloproliferative Disorder Treatment Market – Russia
- 8.4.10.1. Russia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.4.10.2. Russia.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.4.10.3. Russia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.5. Myeloproliferative Disorder Treatment Market – Asia Pacific
- 8.5.1. Asia Pacific: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.5.2. Asia Pacific.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.5.3. Asia Pacific: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.5.4. Myeloproliferative Disorder Treatment Market – China
- 8.5.4.1. China: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.5.4.2. China.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.5.4.3. China: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.5.5. Myeloproliferative Disorder Treatment Market – India
- 8.5.5.1. India: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.5.5.2. India.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.5.5.3. India: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.5.6. Myeloproliferative Disorder Treatment Market – Malaysia
- 8.5.6.1. Malaysia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.5.6.2. Malaysia.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.5.6.3. Malaysia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.5.7. Myeloproliferative Disorder Treatment Market – Japan
- 8.5.7.1. Japan: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.5.7.2. Japan.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.5.7.3. Japan: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.5.8. Myeloproliferative Disorder Treatment Market – Indonesia
- 8.5.8.1. Indonesia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.5.8.2. Indonesia.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.5.8.3. Indonesia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.5.9. Myeloproliferative Disorder Treatment Market – South Korea
- 8.5.9.1. South Korea: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.5.9.2. South Korea.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.5.9.3. South Korea: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.6. Myeloproliferative Disorder Treatment Market – Middle East & Africa
- 8.6.1. Middle East & Africa: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.6.2. Middle East & Africa.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.6.3. Middle East & Africa: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.6.4. Myeloproliferative Disorder Treatment Market – Saudi Arabia
- 8.6.4.1. Saudi Arabia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.6.4.2. Saudi Arabia.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.6.4.3. Saudi Arabia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.6.5. Myeloproliferative Disorder Treatment Market – UAE
- 8.6.5.1. UAE: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.6.5.2. UAE.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.6.5.3. UAE: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.6.6. Myeloproliferative Disorder Treatment Market – Israel
- 8.6.6.1. Israel: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.6.6.2. Israel.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.6.6.3. Israel: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.6.7. Myeloproliferative Disorder Treatment Market – South Africa
- 8.6.7.1. South Africa: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.6.7.2. South Africa.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.6.7.3. South Africa: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.7. Myeloproliferative Disorder Treatment Market – Latin America
- 8.7.1. Latin America: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.7.2. Latin America.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.7.3. Latin America: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.7.4. Myeloproliferative Disorder Treatment Market – Mexico
- 8.7.4.1. Mexico: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.7.4.2. Mexico.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.7.4.3. Mexico: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.7.5. Myeloproliferative Disorder Treatment Market – Brazil
- 8.7.5.1. Brazil: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.7.5.2. Brazil.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.7.5.3. Brazil: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 8.7.6. Myeloproliferative Disorder Treatment Market – Argentina
- 8.7.6.1. Argentina: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.7.6.2. Argentina.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
- 8.7.6.3. Argentina: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
- 10. Company Profiles
- 10.1. AbbVie
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Bristol-Myers Squibb
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Incyte Corporation
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Novartis AG
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Takeda Pharmaceutical Company Limited
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Teva Pharmaceuticals
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Viatris (Mylan N.V.)
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook